AJJ Medtech Holdings Limited Announces Key Milestone in Proposed Share Placement

Overview of the Proposed Placement

AJJ Medtech Holdings Limited (the “Company”), a Singapore-incorporated entity listed on the Catalist board of the Singapore Exchange (SGX-ST), has reached a significant milestone in its proposed placement of new ordinary shares. The Company’s Board has announced the receipt of a listing and quotation notice (LQN) from the SGX-ST, facilitating the potential issuance and listing of up to 127,499,998 new ordinary shares at an issue price of S\$0.0072 per share to selected investors (“Placees”).

Key Points for Investors

• Listing Approval Received: The Company has obtained the necessary approval from the SGX-ST to list and quote the Placement Shares on the Catalist board, subject to full compliance with SGX-ST listing requirements.
• Placement Deadline: The Placement Shares must be placed out within 7 market days from the date of the LQN (19 November 2025). This tight timeline could lead to rapid changes in shareholding structure and potentially impact trading activity in the short term.
• Placement Price: The shares will be issued at S\$0.0072 per share, which may be relevant for investors assessing dilution and valuation implications.
• Size of Placement: The placement involves a substantial number of shares (127,499,998), which could materially increase the total share capital of the Company and may have a dilutive effect on existing shareholders.
• No Indication of Merits: The LQN is an administrative approval and explicitly does not constitute an endorsement of the merits of the Placement, the shares, the Company, or its subsidiaries.
• Further Announcements Pending: The Company will make further announcements upon completion of the Placement and if there are any material developments or changes to the terms of the Placement.

Important Considerations for Shareholders

Trading Caution: Shareholders are strongly advised to exercise caution in trading AJJ Medtech shares at this time. The Placement is subject to certain conditions, and there is no certainty or assurance as of now that the Placement will be completed, nor that there will be no changes to its terms. Any alteration or failure to complete the Placement could influence the share price and ownership structure.

Potential Price Sensitivity: The significant number of shares being placed, and the relatively low Placement Price, could exert downward pressure on the Company’s share price if perceived as dilutive. Conversely, successful completion could improve liquidity or bring in strategic investors, potentially supporting future growth.

Advice for Investors: Investors and shareholders are urged to monitor official Company announcements closely and consult with their stock brokers, bank managers, solicitors, or professional advisors if uncertain about their positions or investment decisions.

Regulatory and Sponsor Notes

The document has been reviewed by the Company’s sponsor, Evolve Capital Advisory Private Limited. However, the SGX-ST has not examined or approved the document and assumes no responsibility for its contents or the accuracy of the information.

For further queries, the contact at Evolve Capital Advisory is Mr. Jerry Chua, reachable at (65) 6241 6626, 160 Robinson Road, #20-01/02, SBF Centre, Singapore 068914.

Conclusion

The receipt of the LQN for the proposed Placement marks a critical step for AJJ Medtech Holdings Limited. With the Placement potentially altering the Company’s share capital and investor base, this development is likely to be price sensitive and merits close attention from shareholders and market participants. As the Placement is not yet completed and subject to conditions, uncertainty remains, and investors should stay vigilant for further updates.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any securities. Investors should conduct their own due diligence and consult professional advisors before making any investment decisions. The information herein is based on official Company disclosures as of 19 November 2025 and may change pending further announcements.

View AJJ Medtech Historical chart here